<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351607</url>
  </required_header>
  <id_info>
    <org_study_id>2020001</org_study_id>
    <nct_id>NCT04351607</nct_id>
  </id_info>
  <brief_title>Preoperative Supplementation of Sucrosomal Iron as Hematopoietic Support.</brief_title>
  <acronym>Preop Iron</acronym>
  <official_title>Einfluss Eines Oralen Eisenpräparats Mit Hoher Bioverfügbarkeit (OLEOvital® EISEN FORTE) Auf Die präoperative Hämoglobinkonzentration Bei anämischen Patienten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mein Hanusch-Krankenhaus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mein Hanusch-Krankenhaus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove, if preoperative elective anemic patients improve their hemoglobin levels within 3-6
      weeks preoperativly after daily oral dietary supplementation of 60mg sucrosomal iron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with preoperative anemia have a poorer perioperative outcome in morbidity and
      mortality as part of surgery. Oral iron preparations have so far had poor bioavailability
      (approx. 30%) and mostly gastrointestinal side effects that often lead to discontinuation of
      treatment. Intravenous iron preparations also have an increased risk of allergic disease,
      which has already led to deaths in Austria. Oleovital® Eisen Forte shows improved
      bioavailability and hardly any gastrointestinal side effects. It should be improved in anemic
      patients by oleovital iron forte the hemoglobin content of the blood before surgery.
      Preoperative anemia is a relatively common problem that has not been preoperatively treated
      so far and therefore studies such as the one present here are very relevant.

      The dietary supplement (Oleovital® Eisen Forte) has been on the market in Austria for iron
      substitution since autumn 2016. Oleovital® Eisen Forte seems suitable to produce a
      physiological hemoglobin content. The improved galenics is without previously known
      gastrointestinal side effects and should be investigated in an oral dose of 2 x 30mg (=60mg)
      p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand.

      The main objective of the study following a confirmant approach is to verify whether a
      sufficiently high number of anemic patients benefit from the oral intake of a high
      bioavailability iron preparation (Oleovital® Eisen Forte) in the last three to six weeks
      before an elective intervention (profit = response = increase in hemoglobin concentration by
      at least 1g/dl).

      This controlled, randomized, open, prospective, monocentric study (two-armed parallel group
      design) should be classified as a food study (application of the commercial dietary
      supplement Oleovital® Eisen Forte) in an interventional setting - study-specific measures:
      additional blood tests and intake of Oleovital® Eisen Forte, in certain cases additional for
      a study-specific blood test are re-quired.

      There are two study arms or groups:

        -  Group V = Verumgroup with iron supplementation by Oleovital® Eisen Forte

        -  Group K = Control group without iron supplementation - This group receives the usual
           treatment in the hospital.

      Furthermore, stratification is carried out according to the sub-collectives

        -  &quot;Patients without menstrual bleeding&quot; (subcollective A) and

        -  &quot;Patients with menstrual bleeding&quot; (subcollective B)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemoglobin</measure>
    <time_frame>3 - 6 weeks</time_frame>
    <description>1 g/dl increase</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia, Iron-Deficiency</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with menstral bleeding - subcollective A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>verum or control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without menstral bleeding - subcollective B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>verum or control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oleovital® Eisen Forte</intervention_name>
    <description>60 mg daily oral Supplementation for 3 to 6 weeks</description>
    <arm_group_label>Patient with menstral bleeding - subcollective A</arm_group_label>
    <arm_group_label>Patient without menstral bleeding - subcollective B</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
    <other_name>Verum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent according to previous written and oral clarification

          -  Elective intervention in 3-6 weeks

          -  Hemoglobin (Hb) -12.0g/dl

          -  Age &gt;18 years

          -  Non-cardiac surgery

        Exclusion Criteria:

          -  Non-business capability or legal representation

          -  Pregnancy

          -  Breastfeeding period

          -  Chronic diarrhoea (&gt; 4 weeks)

          -  Known massive absorption restriction (e.g. short bowel syndrome)

          -  Known or suspected fructose intolerance

          -  Iron accumulation disorders: hemochromatosis, hemosiderosis

          -  Vegan diet

          -  Use of a preparation to specifically increase the body's own erythrocyte or hemoglobin
             concentration or production (e.g. EPO preparations, erythrocyte concentrates) in the
             last 4 weeks

          -  Permanent or preoperativeblood loss (e.g. seepage bleeding)

          -  Intended intake/application of another iron-supplementing preparation before surgery

          -  Intended use of preparations to specifically increase the body's own erythrocyte or
             hemoglobin concentration or production (e.g. EPO preparations, erythrocyte
             concentrates) prior to surgery

          -  Simultaneous participation in another clinical trial with insurance cover

          -  Foreseeable compliance issues

          -  Existing refractory disorder of the bone marrow: myelodysplasia

          -  In the case of conspicuous base laboratory towards undiagnosed hemochromatosis:
             increased plasma iron, increased serum ferritin and increased transferrin saturation
             without increased signs of inflammation (CRP), the patient is assigned to the
             hematological department of the Hanusch Hospital for further diagnosis.

          -  Acutely therapeutic anemia Hb x 8 g/dl (indication for a mandatory correction of the
             Hb to a clinically safe or non-therapeutic value - no randomization into the control
             group makes sense)
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>with or without menstral bleeding</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Loeckinger, M.D.</last_name>
    <phone>+43191021</phone>
    <phone_ext>57158</phone_ext>
    <email>alexander.loeckinger@oegk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Engelbert Deusch, M.D.</last_name>
    <phone>+43191021</phone>
    <phone_ext>57162</phone_ext>
    <email>engelbert.deusch@oegk.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anestesiology and Critical Care Medicine</name>
      <address>
        <city>Vienna</city>
        <state>Penzing</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Loeckinger, M.D.</last_name>
      <phone>+43191021</phone>
      <phone_ext>57158</phone_ext>
      <email>alexander.loeckinger@oegk.at</email>
    </contact>
    <contact_backup>
      <last_name>Engelbert Deusch, M.D.</last_name>
      <phone>+43191021</phone>
      <phone_ext>57162</phone_ext>
      <email>engelbert.deusch@oegk.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mein Hanusch-Krankenhaus</investigator_affiliation>
    <investigator_full_name>Alexander Löckinger MD., Msc.</investigator_full_name>
    <investigator_title>M.D. MSc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

